01 1Ash Stevens LLC
02 1Catalent Micron Technologies, Inc.
01 2Zuranolone
01 2U.S.A
NDC Package Code : 48957-0115
Start Marketing Date : 2023-10-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 69988-0059
Start Marketing Date : 2023-08-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/1)
Marketing Category : DRUG FOR FURTHER PROCESSING
A SAGE-217 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of SAGE-217, including repackagers and relabelers. The FDA regulates SAGE-217 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. SAGE-217 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of SAGE-217 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A SAGE-217 supplier is an individual or a company that provides SAGE-217 active pharmaceutical ingredient (API) or SAGE-217 finished formulations upon request. The SAGE-217 suppliers may include SAGE-217 API manufacturers, exporters, distributors and traders.
click here to find a list of SAGE-217 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing SAGE-217 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for SAGE-217 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture SAGE-217 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain SAGE-217 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a SAGE-217 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of SAGE-217 suppliers with NDC on PharmaCompass.
We have 2 companies offering SAGE-217
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
